The market for targeted radiotherapy in oncology could soon become a bit more competitive as ITM Isotope Technologies Munich unveiled topline Phase III results for ITM-11 (non-carrier-added 177 Lu-edotreotide) in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Radiopharmaceutical Market Glowing As ITM Scores In Phase III
The German firm announced positive topline results for ITM-11 in Grade 1-2 GEP-NETs and plans to seek FDA approval this year.
More from Anticancer
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
More from Scrip
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
Supply chain disruption fears at the start of the COVID-19 pandemic caused drug over-ordering. Imminent tariffs on drugs may have had a similar effect on pharma sales in Q1 earnings season.